Astellas Pharma, Ferring Pharmaceuticals Sign Licensing Agreement for Degarelix, Prostate Cancer Agent.Tokyo, Japan, Feb 1, 2006 - (JCN) - Astellas Pharma announced n January 31 that it has signed a licensing agreement with Ferring Pharmaceuticals on degarelix, Ferring's proprietary agent for treating prostate cancer. Under the agreement terms, Astellas Pharma will be licensed to exclusively develop and market the agent in Japan. Accordingly, Astellas will make upfront and milestone payments as well as royalties on product sales to Ferring Pharmaceuticals. Degarelix, a gonadotropin chorionic gonadotropin , human chorionic gonadotropin (HCG) (hCG) a glycopeptide hormone produced by the fetal placenta syncytiotrophoblasts that maintains the function of the corpus luteum during the first few weeks of pregnancy; the basis for most commonly used pregnancy tests. It is used pharmaceutically to treat certain cases of cryptorchidism and male infertility, to induce ovulation and pregnancy in certain infertile, anovulatory women, and to stimulate oocyte releasing hormone (GnRH GnRH abbr. ) receptor antagonist, helps suppress the testosterone secretion so that it can inhibit the growth of prostate cancer. gonadotropin-releasing hormone Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion